MENU
INBX
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

INBX stock forecast, quote, news & analysis

Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
INBX
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for INBX with price predictions
Oct 21, 2026

INBX in downward trend: 10-day moving average moved below 50-day moving average on October 05, 2026

The 10-day moving average for INBX crossed bearishly below the 50-day moving average on October 05, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.

INBX moved below its 50-day moving average on September 30, 2026 date and that indicates a change from an upward trend to a downward trend.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where INBX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

The Aroon Indicator for INBX entered a downward trend on October 21, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where INBX's RSI Oscillator exited the oversold zone, 29 of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Momentum Indicator moved above the 0 level on October 20, 2026. You may want to consider a long position or call options on INBX as a result. In 68 of 86 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for INBX just turned positive on October 20, 2026. Looking at past instances where INBX's MACD turned positive, the stock continued to rise in 32 of 37 cases over the following month. The odds of a continued upward trend are 86%.

Following a +9.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where INBX advanced for three days, in 226 of 288 cases, the price rose further within the following month. The odds of a continued upward trend are 78%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 6 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-27.278) is normal, around the industry mean (2.988). P/E Ratio (-11.057) is within average values for comparable stocks, (-1.158). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (123.903) among similar stocks. P/S Ratio (1250.000) is also within normal values, averaging (438.009).

The Tickeron Seasonality Score of 30 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is 41 (best 1 - 100 worst), indicating steady price growth. INBX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 47 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Moderna (NASDAQ:MRNA), Regeneron Pharmaceuticals (NASDAQ:REGN), Incyte Corp (NASDAQ:INCY), Exelixis (NASDAQ:EXEL), Arrowhead Pharmaceuticals (NASDAQ:ARWR), Sarepta Therapeutics (NASDAQ:SRPT), Novavax (NASDAQ:NVAX), Nektar Therapeutics (NASDAQ:NKTR), Inovio Pharmaceuticals (NASDAQ:INO), Cel-Sci Corp (ASE:CVM).

Industry description

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

Market Cap

The average market capitalization across the Biotechnology Industry is 2.18B. The market cap for tickers in the group ranges from 58 to 132.95B. VRTX holds the highest valuation in this group at 132.95B. The lowest valued company is SEELQ at 58.

High and low price notable news

The average weekly price growth across all stocks in the Biotechnology Industry was -1%. For the same Industry, the average monthly price growth was -18%, and the average quarterly price growth was -15%. SLN experienced the highest price growth at 119%, while EYPT experienced the biggest fall at -86%.

Volume

The average weekly volume growth across all stocks in the Biotechnology Industry was -21%. For the same stocks of the Industry, the average monthly volume growth was 5% and the average quarterly volume growth was -32%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 50
P/E Growth Rating: 43
Price Growth Rating: 67
SMR Rating: 93
Profit Risk Rating: 93
Seasonality Score: 1 (-100 ... +100)
View a ticker or compare two or three
INBX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

a company, which engages in researching and developing biotechnology

Industry Biotechnology

Industry
N/A
Address
11025 N. Torrey Pines Road
Phone
+1 858 795-4220
Employees
110
Web
https://www.inhibrx.com
INBX in downward trend: 10-day moving average moved below 50-day moving average on October 05, 2026